RecruitingNCT03680677

Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies

Prospective Analysis of Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies

Sponsor

Abramson Cancer Center at Penn Medicine

Enrollment

20 participants

Start Date

Sep 21, 2018

Study Type

OBSERVATIONAL

Conditions

MDS Leukemia, Acute

Summary

The purpose of this research study is to determine if frailty assessments can be used to predict how well patients aged 60 years and older will do after chemotherapy, CAR T-cell therapy, or allogeneic stem cell transplant.

Eligibility

Min Age: 60 Years

Plain Language Summary

Simplified for easier understanding

This trial is studying how a patient's overall physical fitness and health status (called "frailty") affects treatment outcomes for older adults with blood cancers such as leukemia, myelodysplastic syndrome (MDS), lymphoma, or those undergoing stem cell transplant or CAR T-cell therapy. **You may be eligible if (Arm A — newly diagnosed blood cancer)...** - You are 60 years old or older - You have a new or suspected diagnosis of acute leukemia or MDS - You are able to give consent **You may be eligible if (Arm B — transplant or CAR T-cell patients)...** - You are 60 years old or older and have any blood cancer - You are planning to receive a stem cell transplant from a donor, or CAR T-cell therapy - You are able to give consent **You may NOT be eligible if...** - You are younger than 60 years old - You are unable or unwilling to consent to the study - You do not have a qualifying blood cancer diagnosis Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREBone Marrow or Peripheral Blood Graft (BMT)

Patient receives bone marrow or peripheral blood graft (BMT) on or off protocol.

OTHERCancer-directed Therapy or Best Supportive Care

Cancer-directed therapy with intensive regimens ("7+3," Vyxeos, clofarabine, or similar), clinical trial, hypomethylating agent (azacitidine or decitabine), hypomethylating agent combinations (i.e. with venetoclax, sorafenib, enasidenib, ivosidenib, midostaurin, gilteritinib, or other targeted agent), targeted agents alone (i.e. enasidenib, ivosidenib, gilteritinib, midostaurin, etc.), or supportive care.

DIAGNOSTIC_TESTFrailty Assessment

Frailty is the vulnerability of older adults to adverse health outcomes in response to illness and iatrogenic stressors.